SCHEMBL20119784

SCHEMBL20119784

Clc1nc(NCc2ccco2)c2nc(OCC3CCCC3)[nH]c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
KMT2A Q03164 5/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 4/20 0.37
MAPT P10636 4/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPK1 P28482 1/20 0.37
BLM P54132 1/20 0.37
EGFR P00533 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
RECQL P46063 1/20 0.36
PKM P14618 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDE5A O76074 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119944 0.98 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AUSP2ALDH1A1LMNA
SCHEMBL20119806 0.89 SMN1; SMN2 (0.44) SMN1; SMN2KMT2ALMNAMAPTHTT
SCHEMBL20119816 0.88 SMN1; SMN2 (0.45) SMN1; SMN2KMT2AALDH1A1LMNAMAPT
SCHEMBL20119761 0.87 ALDH1A1 (0.46) SMN1; SMN2KMT2AALDH1A1LMNAMAPT
SCHEMBL20119505 0.86 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AALDH1A1LMNAMAPT
SCHEMBL20119792 0.84 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AUSP2ALDH1A1LMNA
SCHEMBL20119674 0.83 SMN1; SMN2 (0.52) SMN1; SMN2KMT2AALDH1A1LMNAMAPT
SCHEMBL20119473 0.82 SMN1; SMN2 (0.50) SMN1; SMN2KMT2ALMNAMAPTHTT
SCHEMBL20119706 0.82 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AUSP2ALDH1A1LMNA
SCHEMBL20119668 0.81 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885USP2 2629/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885USP2 2629/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885USP2 2629/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885USP2 2629/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885KMT2A 2971/4885USP2 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.